石四藥集團(02005.HK)與中國藥科大學成立校企聯合實驗室 於新藥研發等領域展開合作
格隆匯7月6日丨石四藥集團(02005.HK)公吿,公司全資子公司石家莊四藥有限公司("石家莊四藥")和中國藥科大學("乙方")於2021年7月5日簽訂關於建立聯合實驗室合作協議及補充協議,雙方同意利用各自在硬件條件或人才、資金、技術等方面專長,成立校企聯合實驗室,在新藥研發等領域建立長期穩定的合作關係。
協議主要內容如下:1.自雙方協議簽字生效5年內,石家莊四藥每年向聯合實驗室投資人民幣300萬元,共計人民幣1500萬元;2.合作課題包括:1)仿製藥合成工藝方面研究和製劑生物等效性方面研究;2)小分子靶向創新藥物發現研究(抗腫瘤及自身免疫等重大疾病);3.目前乙方涉及11個靶點的15個項目納入合作課題範圍;及4.對於研究成果,石家莊四藥有優先購買權或合作權,購買價格比向第三方轉讓優惠5%。如項目向第三方轉讓,石家莊四藥可獲得每年至少一個項目總額的5%。
雙方並進一步簽訂補充協議,共同推進全合成工藝生產大麻二酚的研究開發、中試放大及產業化,推進大麻二酚藥品的生產、銷售和應用的監管政策落地,推動國家和地方的行政審批。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.